Share on StockTwits

Alexion Pharmaceuticals (NASDAQ:ALXN) CEO Leonard Bell sold 80,458 shares of the stock on the open market in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $160.16, for a total transaction of $12,886,153.28. Following the completion of the sale, the chief executive officer now directly owns 1,027,186 shares of the company’s stock, valued at approximately $164,514,110. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

A number of research firms have recently commented on ALXN. Analysts at Nomura reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $224.00 price target on the stock, up previously from $222.00. Separately, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $222.00 price target on the stock, up previously from $220.00. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $220.00 price target on the stock, up previously from $210.00. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $183.00.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 2.11% during mid-day trading on Wednesday, hitting $164.01. The stock had a trading volume of 783,042 shares. Alexion Pharmaceuticals has a one year low of $100.89 and a one year high of $185.43. The stock’s 50-day moving average is $161.6 and its 200-day moving average is $161.8. The company has a market cap of $32.444 billion and a price-to-earnings ratio of 80.51.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings data on Thursday, July 24th. The company reported $1.12 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.07 by $0.05. The company had revenue of $512.50 million for the quarter, compared to the consensus estimate of $509.54 million. During the same quarter last year, the company posted $0.73 earnings per share. Alexion Pharmaceuticals’s revenue was up 38.5% compared to the same quarter last year. On average, analysts predict that Alexion Pharmaceuticals will post $5.01 earnings per share for the current fiscal year.

Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Receive News & Ratings for Alexion Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.